LATE RELAPSE OF HODGKIN LYMPHOMA ? IS IT DIFFERENT IN CLINICAL CHARACTERISTICS AND OUTCOME?
(Abstract release date: 05/19/16)
EHA Library. Markovic O. 06/09/16; 134757; PB1857
Dr. Olivera Markovic
Contributions
Contributions
Abstract
Abstract: PB1857
Type: Publication Only
Background
Relapse of Hodgkin lymphoma usually occur in 20-30% patients. The disease relapse usually occur within the first 5 years after the diagnosis, with the trend of the diminishing after three years ans subsequently, only minority relapses after 5 years.
Aims
The aim of this study was to evaluate the clinical characteristics, prognostic factors, therapy and outcomes of patients with late relapse (> 5 years).
Methods
We retrospectively analyzed clinical presentation, the prognostic significance of clinical parameters, therapy and outcome in the group of patients with very late relapse of Hodgkin lymphoma and compare them with patients who relapse earlier.
Results
In group of 102 patients with relapsed Hodgkin disease 16(15.68%) patients had very late relapse of disease. Median time to very late relapse was 86 months (range 61 to 199 months). Most of these patients (11, 68.5%) were in advanced clinical stage (III, IV). 11(68.75%) patients with very late relapse were treated with high dose chemotherapy and autologous bone marrow transplantation. Second complete response was achieved in 13(81.25%) patients. At a median of 4,5 years after therapy for very late relapse, 13(81.25%) patients are still alive and free of disease and 3 patients died: 2 patients from Hodgkin lymphoma, and one patient from brain tumor. There was not noticed significant difference between initial clinical parameters between of patients with very late relapse and patients who relapse earlier. Median survival of patients with very late relapse of disease was significantly longer (p=0.001). However, survival calculated from the moment оf relapse of disease was not significantly different between these two group of patients (p=0.83).
Conclusion
The late relapse is relatively rare event in our group of patients with Hodgkin lymphoma. Patients with very late relapse have longer OS, than the patients who relapse earlier, but survival calculated from relapse was not significantly different. Remains an open question is it necessary to apply high dose therapy and autologous transplantation in all patients with very late relapse of disease. Further clinical trials are needed to characterize best therapy option in patients with very late relapse tailored to disease risk and comorbidities.
Session topic: E-poster
Keyword(s): Hodgkin's lymphoma, Prognosis, Recurrence, Therapy
Type: Publication Only
Background
Relapse of Hodgkin lymphoma usually occur in 20-30% patients. The disease relapse usually occur within the first 5 years after the diagnosis, with the trend of the diminishing after three years ans subsequently, only minority relapses after 5 years.
Aims
The aim of this study was to evaluate the clinical characteristics, prognostic factors, therapy and outcomes of patients with late relapse (> 5 years).
Methods
We retrospectively analyzed clinical presentation, the prognostic significance of clinical parameters, therapy and outcome in the group of patients with very late relapse of Hodgkin lymphoma and compare them with patients who relapse earlier.
Results
In group of 102 patients with relapsed Hodgkin disease 16(15.68%) patients had very late relapse of disease. Median time to very late relapse was 86 months (range 61 to 199 months). Most of these patients (11, 68.5%) were in advanced clinical stage (III, IV). 11(68.75%) patients with very late relapse were treated with high dose chemotherapy and autologous bone marrow transplantation. Second complete response was achieved in 13(81.25%) patients. At a median of 4,5 years after therapy for very late relapse, 13(81.25%) patients are still alive and free of disease and 3 patients died: 2 patients from Hodgkin lymphoma, and one patient from brain tumor. There was not noticed significant difference between initial clinical parameters between of patients with very late relapse and patients who relapse earlier. Median survival of patients with very late relapse of disease was significantly longer (p=0.001). However, survival calculated from the moment оf relapse of disease was not significantly different between these two group of patients (p=0.83).
Conclusion
The late relapse is relatively rare event in our group of patients with Hodgkin lymphoma. Patients with very late relapse have longer OS, than the patients who relapse earlier, but survival calculated from relapse was not significantly different. Remains an open question is it necessary to apply high dose therapy and autologous transplantation in all patients with very late relapse of disease. Further clinical trials are needed to characterize best therapy option in patients with very late relapse tailored to disease risk and comorbidities.
Session topic: E-poster
Keyword(s): Hodgkin's lymphoma, Prognosis, Recurrence, Therapy
Abstract: PB1857
Type: Publication Only
Background
Relapse of Hodgkin lymphoma usually occur in 20-30% patients. The disease relapse usually occur within the first 5 years after the diagnosis, with the trend of the diminishing after three years ans subsequently, only minority relapses after 5 years.
Aims
The aim of this study was to evaluate the clinical characteristics, prognostic factors, therapy and outcomes of patients with late relapse (> 5 years).
Methods
We retrospectively analyzed clinical presentation, the prognostic significance of clinical parameters, therapy and outcome in the group of patients with very late relapse of Hodgkin lymphoma and compare them with patients who relapse earlier.
Results
In group of 102 patients with relapsed Hodgkin disease 16(15.68%) patients had very late relapse of disease. Median time to very late relapse was 86 months (range 61 to 199 months). Most of these patients (11, 68.5%) were in advanced clinical stage (III, IV). 11(68.75%) patients with very late relapse were treated with high dose chemotherapy and autologous bone marrow transplantation. Second complete response was achieved in 13(81.25%) patients. At a median of 4,5 years after therapy for very late relapse, 13(81.25%) patients are still alive and free of disease and 3 patients died: 2 patients from Hodgkin lymphoma, and one patient from brain tumor. There was not noticed significant difference between initial clinical parameters between of patients with very late relapse and patients who relapse earlier. Median survival of patients with very late relapse of disease was significantly longer (p=0.001). However, survival calculated from the moment оf relapse of disease was not significantly different between these two group of patients (p=0.83).
Conclusion
The late relapse is relatively rare event in our group of patients with Hodgkin lymphoma. Patients with very late relapse have longer OS, than the patients who relapse earlier, but survival calculated from relapse was not significantly different. Remains an open question is it necessary to apply high dose therapy and autologous transplantation in all patients with very late relapse of disease. Further clinical trials are needed to characterize best therapy option in patients with very late relapse tailored to disease risk and comorbidities.
Session topic: E-poster
Keyword(s): Hodgkin's lymphoma, Prognosis, Recurrence, Therapy
Type: Publication Only
Background
Relapse of Hodgkin lymphoma usually occur in 20-30% patients. The disease relapse usually occur within the first 5 years after the diagnosis, with the trend of the diminishing after three years ans subsequently, only minority relapses after 5 years.
Aims
The aim of this study was to evaluate the clinical characteristics, prognostic factors, therapy and outcomes of patients with late relapse (> 5 years).
Methods
We retrospectively analyzed clinical presentation, the prognostic significance of clinical parameters, therapy and outcome in the group of patients with very late relapse of Hodgkin lymphoma and compare them with patients who relapse earlier.
Results
In group of 102 patients with relapsed Hodgkin disease 16(15.68%) patients had very late relapse of disease. Median time to very late relapse was 86 months (range 61 to 199 months). Most of these patients (11, 68.5%) were in advanced clinical stage (III, IV). 11(68.75%) patients with very late relapse were treated with high dose chemotherapy and autologous bone marrow transplantation. Second complete response was achieved in 13(81.25%) patients. At a median of 4,5 years after therapy for very late relapse, 13(81.25%) patients are still alive and free of disease and 3 patients died: 2 patients from Hodgkin lymphoma, and one patient from brain tumor. There was not noticed significant difference between initial clinical parameters between of patients with very late relapse and patients who relapse earlier. Median survival of patients with very late relapse of disease was significantly longer (p=0.001). However, survival calculated from the moment оf relapse of disease was not significantly different between these two group of patients (p=0.83).
Conclusion
The late relapse is relatively rare event in our group of patients with Hodgkin lymphoma. Patients with very late relapse have longer OS, than the patients who relapse earlier, but survival calculated from relapse was not significantly different. Remains an open question is it necessary to apply high dose therapy and autologous transplantation in all patients with very late relapse of disease. Further clinical trials are needed to characterize best therapy option in patients with very late relapse tailored to disease risk and comorbidities.
Session topic: E-poster
Keyword(s): Hodgkin's lymphoma, Prognosis, Recurrence, Therapy
{{ help_message }}
{{filter}}